Company intelligence / Profile preview

COMED Group

Ownership: Private
Development stage: Other

Overview

COMED Therapeutics develops innovative RNA-based therapies delivered via proprietary nano lipid particles, initially targeting pancreatic cancer with plans to expand into additional critical disease areas. The company emphasizes scientific excellence and collaboration with leading pharmaceutical partners but has not yet published detailed clinical results or advanced programs into late-stage trials as of June 2025.

Therapeutic areas: Critical CareOncology
Modalities: mRNA-based drugsNano lipid particle delivery therapy
Industry: Biotech

Beyond the preview

Go deeper on COMED Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COMED Group.

Explore the full profile